Syndax Pharmaceuticals Inc (SNDX.OQ)
20 Apr 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2008||Independent Chairman of the Board|
|46||2015||President, Chief Operating Officer|
|57||2015||Chief Executive Officer, Director|
|64||2017||Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer|
|66||2015||Senior Vice President, Chief Development Officer|
- BRIEF-Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80
- BRIEF-Syndax Pharmaceuticals Reports Qtrly Loss Per Share $0.80
- BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca
- BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
- BRIEF-Syndax Pharmaceuticals reports Q3 loss per share $0.68